For psychedelic investors, finding the next breakthrough company is the difficult part. Neo Kuma Ventures appears to have made at least one remarkably well-timed bet.
The London-based venture capital firm was an early investor in Atai Life Sciences and Beckley Psytech, two companies that went on to combine as AtaiBeckley and develop one of the sector’s most advanced psychedelic drug programmes.
The most significant validation came in July 2026, when Eli Lilly agreed to acquire AtaiBeckley for approximately US$2.8 billion in upfront cash, with the total consideration potentially reaching US$3.8 billion if development and regulatory milestones are achieved.
At the centre of the deal is BPL-003, an intranasal formulation of 5-MeO-DMT being developed for treatment-resistant depression. Lilly’s acquisition gives the pharmaceutical giant access to a late-stage psychedelic programme as it expands its neuroscience pipeline.
For Neo Kuma, the significance of the transaction goes back years.
An early bet on psychedelic medicine
Neo Kuma says it invests in early-stage psychedelic healthcare companies, typically committing between £150,000 and £1 million from pre-seed through Series A. Its focus spans drug development, clinics and care delivery, digital therapeutics and technology platforms, with a global investment strategy and a European tilt.
Atai was among its earliest investments.
According to reporting from 2021, Neo Kuma had invested around £500,000 across multiple Atai funding rounds. Beckley Psytech was also among the fund’s initial investments, putting Neo Kuma in both companies well before their eventual combination and Lilly transaction.
AtaiBeckley was formed through the 2025 combination of Atai Life Sciences and Beckley Psytech. Its lead programme, BPL-003, subsequently became one of the most advanced psychedelic drug candidates in development for treatment-resistant depression.
That makes the Lilly deal more than another large pharmaceutical transaction involving psychedelics.
It is an example of the investment model specialist funds like Neo Kuma are built around: identify promising science early, provide capital while clinical and regulatory risk remains high, and ultimately look for the asset to become attractive to much larger pharmaceutical investors.
Beyond BPL-003
Neo Kuma’s portfolio is broader than a single drug.
The firm currently lists investments including Atai Life Sciences, Beckley Psytech, Bright Minds, Kanna Health, Small Pharma, Journey Clinical, Wavepaths, Awakn Life Sciences, Sana Health, Monument Therapeutics, TRIPP and Neurocentrx.
The portfolio reflects the different approaches being taken to commercialise psychedelic medicine.
Some companies are developing new compounds. Others are building clinical infrastructure, digital therapeutics or technology designed to support psychedelic-assisted care.
Awakn provides another example of Neo Kuma’s approach.
In 2021, Neo Kuma participated in an C$8.3 million private placement for Awakn Life Sciences, alongside other investors. The financing supported Awakn’s development of ketamine-assisted therapy programmes targeting mental health and addiction.
The common thread is that Neo Kuma has generally entered companies before the commercial model is fully proven.
That is where the potential upside lies — but also where much of the risk remains.
The BPL-003 test
BPL-003 provides the clearest example of what that early-stage strategy can look like when the clinical development progresses.
In its Phase 2b trial, 193 patients with moderate-to-severe treatment-resistant depression were randomised to receive a single 8 mg, 12 mg or 0.3 mg comparator dose. The 8 mg and 12 mg groups both produced statistically significant improvements in MADRS scores compared with the comparator at Day 29, with statistically significant differences emerging as early as Day 2 and effects remaining evident through Day 57.
The 8 mg dose was subsequently selected for Phase 3 development.
Those results do not mean BPL-003 is an approved treatment, or that the programme is guaranteed to succeed. But they helped move the asset from an early-stage psychedelic drug programme towards the kind of clinical development that can attract major pharmaceutical capital.
That is ultimately the bet specialist healthcare investors are making.
Not hype.
Not simply another funding round.
Clinical evidence strong enough to make a programme commercially relevant to mainstream pharmaceutical companies.
What the deal means for psychedelic investors
The Lilly acquisition does not prove that the broader psychedelic sector has reached commercial maturity. Most companies developing psychedelic medicines remain highly speculative, and clinical, regulatory and financing risks remain substantial.
It does, however, provide a tangible example of the path the sector has been trying to establish.
Neo Kuma backed Atai and Beckley when both were much earlier in their development. Years later, the businesses combined, BPL-003 advanced into late-stage development, and Lilly agreed to pay up to US$3.8 billion for the resulting company.
For Neo Kuma, that is a considerably more useful outcome than simply being able to point to a successful portfolio company.
It demonstrates the potential value of specialist investors who can identify credible science before it becomes obvious to the broader pharmaceutical market.
As psychedelic healthcare moves from experimental research towards regulated medicines, that ability to recognise promising programmes early — and fund them through the long, expensive process of clinical development — could become one of the sector’s most valuable forms of capital.
